Investor Presentaiton
Timelines - PR, Financial and Commercial
TC
BIOPHARM
Recent Milestones
Completed ACHIEVE Safety Cohort and
received positive review from the Data
Safety Monitoring Board (DSMB)
. FDA clearance of investigational new drug
(IND) application for a Phase 1B study in
relapse/refractory Acute Myeloid
Leukemia (AML)
.
• Restructured business for annual cost
savings of $7-10M
QMUL project received grant funding from
The Impact Fund arm of QMUL, to
research the therapeutic potential of
gamma-delta T cells for the treatment of
mucosal infections.
Formed a third-party manufacturing
partnership in US with Excellos
2024 Target Milestones
• Launch of ACHIEVE 2 Trial
• Execute partnership/collaboration in
combination with TCB-008
•
Establish proof of Concept for anti-
fungal/anti-bacterial and expansion
of platform
17View entire presentation